AMGN Stock Analysis: Amgen | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 220.275m USD | 12M Return: 45.1% | US0311621009 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.15B
EPS Trend: 96.7%
Qual. Beats: 8
Rev. Trend: 98.2%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amgen Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics, operating within the biotechnology sub-industry of the healthcare sector. The company markets a broad portfolio of biologic and small-molecule therapies spanning oncology, inflammation, bone health, cardiovascular disease, hematology, and rare diseases, including blockbusters such as Enbrel, Prolia, Repatha, Otezla, and KYPROLIS. As one of the largest independent biotechnology firms, Amgen is distinguished by its focus on biologic medicines rather than traditional small-molecule drugs.
Amgen distributes its products primarily through pharmaceutical wholesale distributors, serving healthcare providers such as physicians, dialysis centers, hospitals, and pharmacies. The company pursues a strategy of pairing internally developed therapies with external collaboration and licensing deals, including partnerships with AstraZeneca for TEZSPIRE, UCB for EVENITY, and Kyowa Kirin for rocatinlimab. Founded in 1980 and headquartered in the United States, Amgen has been publicly traded since 1983 and operates at mega-cap scale, reflecting its position among the worlds largest biotechnology companies.
- MariTide obesity drug faces competitive pressure from Lilly and Novo
- Enbrel and Prolia biosimilar erosion weighs on legacy franchise revenue
- Horizon Therapeutics acquisition adds debt and rare disease growth
| Net Income: 8.74b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.43 > 1.0 |
| NWC/Revenue: 24.81% < 20% (prev 17.93%; Δ 6.88% < -1%) |
| CFO/TA 0.13 > 3% & CFO 12.5b > Net Income 8.74b |
| Net Debt (43.3b) to EBITDA (17.6b): 2.46 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (544.0m) vs 12m ago 0.55% < -2% |
| Gross Margin: 72.65% > 18% (prev 64.47%; Δ 8.18% > 0.5%) |
| Asset Turnover: 41.54% > 50% (prev 39.71%; Δ 1.83% > 0%) |
| Interest Coverage Ratio: 4.86 > 6 (EBIT TTM 13.0b / Interest Expense TTM 2.67b) |
| A: 0.10 (Total Current Assets 35.0b - Total Current Liabilities 25.5b) / Total Assets 95.6b |
| B: -0.23 (Retained Earnings -22.3b / Total Assets 95.6b) |
| C: 0.14 (EBIT TTM 13.0b / Avg Total Assets 91.8b) |
| D: 0.14 (Book Value of Equity 11.7b / Total Liabilities 84.0b) |
| Altman-Z'' = 0.98 = BB |
| DSRI: 1.08 (Receivables 10.2b/8.70b, Revenue 38.1b/34.9b) |
| GMI: 0.89 (GM 64.47% / 72.65%) |
| AQI: 0.88 (AQ_t 0.55 / AQ_t-1 0.62) |
| SGI: 1.09 (Revenue 38.1b / 34.9b) |
| TATA: -0.04 (NI 8.74b - CFO 12.5b) / TA 95.6b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 15, 2026, the stock is trading at USD 412.84 with a total of 2,319,532 shares traded. Over the past week, the price has changed by +2.54%, over one month by +8.21%, over three months by +15.20% and over the past year by +45.11%.
Current recommended Stop Loss: 386.60 (which is 6.4% or 2.6 ATR below the current price).
Amgen has received a consensus analysts rating of 3.35. Therefore, it is recommended to hold AMGN.
- StrongBuy: 8
- Buy: 4
- Hold: 17
- Sell: 2
- StrongSell: 3
| Analysts Target Price | 391.5 | -5.2% |
P/E Trailing = 25.3068
P/E Forward = 16.6667
P/S = 5.7823
P/B = 18.7838
P/EG = 2.4515
Revenue TTM = 38.1b USD
EBIT TTM = 13.0b USD
EBITDA TTM = 17.6b USD
Long Term Debt = 51.9b USD (from longTermDebt, last quarter)
Short Term Debt = 5.45b USD (from shortTermDebt, last quarter)
Debt = 57.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 43.3b USD (calculated: Debt 57.3b - CCE 14.0b)
Enterprise Value = 264b USD (220b + Debt 57.3b - CCE 14.0b)
Interest Coverage Ratio = 4.86 (Ebit TTM 13.0b / Interest Expense TTM 2.67b)
EV/FCF = 25.91x (Enterprise Value 264b / FCF TTM 10.2b)
FCF Yield = 3.86% (FCF TTM 10.2b / Enterprise Value 264b)
FCF Margin = 26.69% (FCF TTM 10.2b / Revenue TTM 38.1b)
Net Margin = 22.93% (Net Income TTM 8.74b / Revenue TTM 38.1b)
Gross Margin = 72.65% ((Revenue TTM 38.1b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 72.04% (prev 68.16%)
Tobins Q-Ratio = 2.76 (Enterprise Value 264b / Total Assets 95.6b)
Interest Expense / Debt = 4.66% (Interest Expense 2.67b / Debt 57.3b)
Taxrate = 15.01% (1.54b / 10.3b)
NOPAT = 11.0b (EBIT 13.0b * (1 - 15.01%))
Current Ratio = 1.37 (Total Current Assets 35.0b / Total Current Liabilities 25.5b)
Debt / Equity = 4.90 (Debt 57.3b / totalStockholderEquity, last quarter 11.7b)
Debt / EBITDA = 2.46 (Net Debt 43.3b / EBITDA 17.6b)
Debt / FCF = 4.26 (Net Debt 43.3b / FCF TTM 10.2b)
Total Stockholder Equity = 9.79b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.53% (Net Income 8.74b / Total Assets 95.6b)
RoE = 89.32% (Net Income TTM 8.74b / Total Stockholder Equity 9.79b)
RoCE = 21.01% (EBIT 13.0b / Capital Employed (Equity 9.79b + L.T.Debt 51.9b))
RoIC = 14.94% (NOPAT 11.0b / Invested Capital 73.7b)
WACC = 5.98% (E(220b)/V(278b) * Re(6.51%) + D(57.3b)/V(278b) * Rd(4.66%) * (1-Tc(0.15)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.20 | Cagr: 0.66%
[DCF] Terminal Value 74.87% ; FCFF base≈10.3b ; Y1≈10.0b ; Y5≈9.92b
[DCF] Fair Price = 207.5 (EV 156b - Net Debt 43.3b = Equity 112b / Shares 540.6m; r=8.35% [WACC [floored]]; 5y FCF grow -4.05% → 2.50% )
EPS Correlation: 96.74 | EPS CAGR: 9.14% | SUE: 2.73 | # QB: 8
Revenue Correlation: 98.18 | Revenue CAGR: 13.24% | SUE: 3.08 | # QB: 1
EPS current Quarter (2026-09-30): EPS=5.79 | Chg30d=+0.13% | Revisions=+12% | Analysts=27
EPS current Year (2026-12-31): EPS=23.05 | Chg30d=+0.06% | Revisions=+40% | GrowthEPS=+5.6% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=24.47 | Chg30d=+0.26% | Revisions=+30% | GrowthEPS=+6.2% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +23% (up=20, down=12)